Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRISM-1: Quemliclustat plus nab-paclitaxel and gemcitabine vs placebo plus nab-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma
jRCT2061240084Phase 3Active, not recruiting
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Jan 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in pancreatic adenocarcinoma (PDAC) comparing Quemliclustat + nab-paclitaxel + gemcitabine with Placebo + nab-paclitaxel + gemcitabine (2 arms). Primary endpoint: Overall survival. Started Jan 2025; status: active, not recruiting.
02
Drugs
quemliclustat
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on jRCT2061240084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061240084.